1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Squamous Cell Carcinoma Global Clinical Trials Review, H1, 2014

Squamous Cell Carcinoma Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Squamous Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Squamous Cell Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Squamous Cell Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Squamous Cell Carcinoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Squamous Cell Carcinoma Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents2
List of Tables 4
List of Figures 5
Introduction 6
Squamous Cell Carcinoma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Squamous Cell Carcinoma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Squamous Cell Carcinoma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Squamous Cell Carcinoma 25
Subjects Recruited Over a Period of Time 33
Clinical Trials by Sponsor Type 34
Prominent Sponsors 35
Top Companies Participating in Squamous Cell Carcinoma Therapeutics Clinical Trials 36
Prominent Drugs 38
Latest Clinical Trials News on Squamous Cell Carcinoma 39
Nov 05, 2013: ImmunoGen Initiates Phase I Testing of Its EGFR-Targeting ADC, IMGN289 39
Sep 09, 2013: Oncolytics Biotech Announces Positive Final Tumour Response Data for U.S. Phase 2 Study of REOLYSIN in Squamous Cell Lung Cancer 39
Jul 02, 2013: VentiRx Pharmaceuticals Initiates the ACTIVE8 Phase 2 Clinical Trial Evaluating VTX-2337 in Combination with Cetuximab and Chemotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck 40
Mar 28, 2013: Oncolytics Biotech Meets Primary Overall Statistical Endpoint In US Phase II Study Of Reolysin In Squamous Cell Lung Cancer 40
Feb 08, 2013: Oncolytics Biotech Announces Additional Positive Reolysin Clinical Trial Data From Phase II Study In Squamous Cell Carcinoma Of Lung 41
Clinical Trial Profiles 42
Clinical Trial Overview of Top Companies 42
Pfizer Inc. 42
Clinical Trial Overview of Pfizer Inc. 42
GlaxoSmithKline plc 43
Clinical Trial Overview of GlaxoSmithKline plc 43
Sanofi 44
Clinical Trial Overview of Sanofi 44
AstraZeneca PLC 45
Clinical Trial Overview of AstraZeneca PLC 45
Bristol-Myers Squibb Company 46
Clinical Trial Overview of Bristol-Myers Squibb Company 46
Novartis AG 47
Clinical Trial Overview of Novartis AG 47
E. Merck KG 48
Clinical Trial Overview of E. Merck KG 48
Amgen Inc. 49
Clinical Trial Overview of Amgen Inc. 49
Merck and Co., Inc. 50
Clinical Trial Overview of Merck and Co., Inc. 50
Eli Lilly and Company 51
Clinical Trial Overview of Eli Lilly and Company 51
Clinical Trial Overview of Top Institutes / Government 52
National Cancer Institute 52
Clinical Trial Overview of National Cancer Institute 52
The University of Texas M. D. Anderson Cancer Center 65
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 65
European Organization for Research and Treatment of Cancer 67
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 67
Gynecologic Oncology Group 69
Clinical Trial Overview of Gynecologic Oncology Group 69
Memorial Sloan Kettering Cancer Center 71
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 71
Radiation Therapy Oncology Group 73
Clinical Trial Overview of Radiation Therapy Oncology Group 73
Roswell Park Cancer Institute 75
Clinical Trial Overview of Roswell Park Cancer Institute 75
Mayo Clinic 76
Clinical Trial Overview of Mayo Clinic 76
Stanford University 77
Clinical Trial Overview of Stanford University 77
FUDAN University 78
Clinical Trial Overview of FUDAN University 78
Five Key Clinical Profiles 79
Appendix 108
Abbreviations 108
Definitions 108
Research Methodology 109
Secondary Research 109
About GlobalData 110
Contact Us 110
Disclaimer 110
Source 111

List of Tables
Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials by Region, 2014* 7
Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Squamous Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Squamous Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Squamous Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Squamous Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Squamous Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Squamous Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Squamous Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Squamous Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Squamous Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Squamous Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Squamous Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Squamous Cell Carcinoma Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Squamous Cell Carcinoma Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Squamous Cell Carcinoma Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 33
Squamous Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 34
Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 35
Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 37
Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 38
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 42
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 43
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 44
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 45
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 46
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 47
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by E. Merck KG, 2014* 48
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 49
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 50
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 51
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 52
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 65
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 67
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Gynecologic Oncology Group, 2014* 69
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 71
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Radiation Therapy Oncology Group, 2014* 73
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Roswell Park Cancer Institute, 2014* 75
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014* 76
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 77
Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by FUDAN University, 2014* 78

List of Figures
Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Squamous Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Squamous Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Squamous Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Squamous Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Squamous Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Squamous Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Squamous Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Squamous Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Squamous Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Squamous Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Squamous Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 33
Squamous Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 34
Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 35
Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 36
Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 38
GlobalData Methodology 109

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy
Cancer
Clinical Trial
Chemotherapy

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.